The improvements in emotional regulation realized through MBCT contribute to a reduction in depressive symptoms (Alanko et al., 2022; Leichsenring et al., 2016; Meadows et al., 2014), cortisol levels (Zhang et al., 2023), oxidative stress (Liu et al., 2015), and an increase in metabolism (Henje Blom et al., 2015), serum Brain-Derived Neurotrophic Factor (BDNF) (Autry and Monteggia, 2012) and neuroplasticity affected by MDD (Eyre and Baune, 2012). The gene discussed is BDNF; the disease is major depressive disorder.